Cerebrospinal Fluid Amyloid-β (Aβ) as an Effect Biomarker for Brain Aβ Lowering Verified by Quantitative Preclinical Analyses
Yasong Lu(Pfizer (United States)), Martin Pettersson, Jason Barricklow, Michael A. Brodney(Vertex Pharmaceuticals (United States)), David Riddell(Eli Lilly (United States)), Kathleen M. Wood, Emily Happy Miller, Douglas S. Johnson(Biogen (United States)), Elaine Tseng(University of California, San Francisco), Charles E. Nolan(Pfizer (United States)), Ashley Robshaw(Pfizer (United States)), Liming Zhang(North China University of Technology), Brian T. O’Neill(Pfizer (United States)), Stacey L. Becker(Pfizer (United States)), Louis Leung(Merck & Co., Inc., Rahway, NJ, USA (United States)), Éva Hajós‐Korcsok(Pfizer (United States)), Sarah M. Osgood, Kelly R. Bales(Eli Lilly (United States))
Cited by 36
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
|Nature Neuroscience|2002|858
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
|Nature Genetics|1997|835
Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein
|Proceedings of the National Academy of Sciences|2005|659
Murine Mammary Carcinoma Exosomes Promote Tumor Growth by Suppression of NK Cell Function
|The Journal of Immunology|2006|487